Pancreatic islet of Langerhans

Pancreatic islets of Langerhans are highly vascularized clusters of endocrine cells scattered throughout the exocrine tissue of the pancreas that are essential for maintaining systemic glucose homeostasis (StatPearls, 2023). They are composed of several specialized cell types, most notably beta cells which produce insulin, alpha cells which produce glucagon, and delta cells which produce somatostatin (NIH, 2022). In Type 1 Diabetes, the beta cells are selectively destroyed by an autoimmune process, whereas Type 2 Diabetes is characterized by progressive beta-cell dysfunction and failure to compensate for insulin resistance (PubMed, 2021). Therapeutic strategies targeting these cells include pharmacological agents that enhance insulin secretion, such as GLP-1 receptor agonists, and cellular replacement therapies like islet transplantation for patients with severe glycemic instability (Nature Reviews Endocrinology, 2020). Current research focuses on protecting islet mass from inflammatory stress and developing stem-cell-derived islet cells to overcome the shortage of donor tissue (Lancet Diabetes & Endocrinology, 2021).

Other names

Human islet cellsPancreatic isletsIslets of LangerhansEndocrine pancreasIslet of Langerhans

Drugs interact with islet cells through several distinct mechanisms: sulfonylureas bind to the SUR1 subunit of ATP-sensitive potassium channels to stimulate insulin release; GLP-1 receptor agonists enhance glucose-dependent insulin secretion via cAMP signaling; and DPP-4 inhibitors prevent the degradation of incretin hormones (StatPearls, 2023). In the context of islet transplantation, immunosuppressive agents like calcineurin inhibitors are used to prevent T-cell mediated rejection of the donor cells (NIH, 2022).